With sales of Korlym (mifepristone), the leading Cushing’s disease drug, forecast to start falling next year, Corcept Therapeutics Incorporated needs a new money-spinner. Thanks to a hit in the pivotal GRACE trial, it appears to have one in relacorilant.
Key Takeaways
- The GRACE trial of Corcept Therapeutics’ Cushing’s disease candidate relacorilant has succeeded in its pivotal trial.
Relacorilant, like its predecessor, aims to treat Cushing’s by modulating cortisol levels by competing with it at the glucocorticoid receptor....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?